MNKD Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
MannKind Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.88 |
| 52 Week High | US$7.63 |
| 52 Week Low | US$3.17 |
| Beta | 1.3 |
| 11 Month Change | 3.93% |
| 3 Month Change | 29.08% |
| 1 Year Change | 88.49% |
| 33 Year Change | 41.86% |
| 5 Year Change | 483.05% |
| Change since IPO | -90.23% |
Recent News & Updates
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
Oct 03MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 18
Recent updates
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
Oct 03MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 18Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Jul 17MannKind Outperforms As Tyvaso DPI Captures Market Share
May 15This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Mar 03MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Mar 02MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Feb 15MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
Jan 03Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price
May 15MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Jan 27Mannkind Corporation: Ready For Your Biotech Portfolio
Sep 01New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)
Aug 19MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed
Aug 09MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?
Feb 25MannKind: A Promising Player In The Inhalable Insulin Market
Feb 08US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results
Aug 14Lytham Partners Summer 2021 Investor Conference
Jun 14MannKind (MNKD) Investor Presentation - Slideshow
Jun 04MannKind reduces debt by $49.5M and restructures remaining obligations
Apr 26Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?
Feb 22MannKind to co-promote Thyquidity
Dec 17Shareholder Returns
| MNKD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.1% | -6.5% | -1.0% |
| 1Y | 88.5% | 14.6% | 30.3% |
Return vs Industry: MNKD exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: MNKD exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| MNKD volatility | |
|---|---|
| MNKD Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MNKD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MNKD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 413 | Michael Castagna | www.mannkindcorp.com |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company’s product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).
MannKind Corporation Fundamentals Summary
| MNKD fundamental statistics | |
|---|---|
| Market cap | US$1.89b |
| Earnings (TTM) | US$21.57m |
| Revenue (TTM) | US$267.20m |
88.0x
P/E Ratio7.1x
P/S RatioIs MNKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNKD income statement (TTM) | |
|---|---|
| Revenue | US$267.20m |
| Cost of Revenue | US$75.07m |
| Gross Profit | US$192.14m |
| Other Expenses | US$170.57m |
| Earnings | US$21.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.078 |
| Gross Margin | 71.91% |
| Net Profit Margin | 8.07% |
| Debt/Equity Ratio | -108.6% |
How did MNKD perform over the long term?
See historical performance and comparison